Filing Flows

Filing Flows › Companies › Chemours › Cash flow

Chemours cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$98.0M in Q3 2026 · $211M over twelve months

Operating cash flow$149M
Capital spending−$51.0M
Free cash flow+$98.0M
Cash / net income0.8×
Cash conversion cycle81 days

Analysis

In Q3 2026, Chemours generated $149M of operating cash flow and spent $51.0M on capital projects, leaving free cash flow of $98.0M. That is $7.0M less than in Q3 2025 ($105M).

Over the twelve months to Sep 30, 2026, operating cash flow was $400M; the largest uses were other financing ($1.7B), capital spending ($189M), dividends ($54.0M); besides operations, cash came from net borrowing (+) / repaid (−) ($1.3B), asset & business sales ($342M); the cash balance rose by $136M.

Operating cash flow was $149M against net income of $196M — 0.8× profit, less cash than reported earnings, worth checking against working capital. The largest differences: other liabilities −$158M, depreciation & amortization +$79.0M, gains on disposals −$50.0M.

Its cash conversion cycle was 81 days (receivables 46 + inventory 103 − payables 68).

Free cash flow

Chemours: free cash flow by quarterChemours: free cash flow by quarter$29.0MQ4 2024−$196MQ1 2025$50.0MQ2 2025$105MQ3 2025$92.0MQ4 2025−$93.0MQ1 2026$114MQ2 2026$98.0MQ3 2026
Operating cash flow less capital spending.
Chemours: operating cash flow against capital spendingChemours: operating cash flow against capital spendingOperating cash flowCapital spending$138M$109MQ4 2024−$112M$84.0MQ1 2025$93.0M$43.0MQ2 2025$146M$41.0MQ3 2025$137M$45.0MQ4 2025−$44.0M$49.0MQ1 2026$158M$44.0MQ2 2026$149M$51.0MQ3 2026
Latest (Q3 2026): Operating cash flow $149M, Capital spending $51.0M.

Capital allocation, year by year

Chemours: where the cash came from (up) and went (down), by fiscal yearChemours: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksDividendsFY2021: Operating cash flow $814MFY2021: Net borrowing $640MFY2021: Shares issued $23.0MFY2021: Asset sales $508MFY2021: Capital spending −$277MFY2021: Buybacks −$173MFY2021: Dividends −$164M$2.0BFY2021FY2022: Operating cash flow $755MFY2022: Net borrowing −$11.0MFY2022: Shares issued $51.0MFY2022: Asset sales $33.0MFY2022: Capital spending −$307MFY2022: Buybacks −$495MFY2022: Dividends −$154M$839MFY2022FY2023: Operating cash flow $556MFY2023: Net borrowing $637MFY2023: Shares issued $19.0MFY2023: Asset sales $143MFY2023: Capital spending −$370MFY2023: Buybacks −$69.0MFY2023: Dividends −$149M$1.4BFY2023FY2024: Operating cash flow −$633MFY2024: Net borrowing $594MFY2024: Shares issued $9.0MFY2024: Asset sales $3.0MFY2024: Capital spending −$360MFY2024: Dividends −$148M$606MFY2024FY2025: Operating cash flow $264MFY2025: Net borrowing $734MFY2025: Asset sales $7.0MFY2025: Capital spending −$213MFY2025: Dividends −$78.0M$1.0BFY2025
Over these 5 years operating cash flow totalled $1.8B; the largest uses were capital spending ($1.5B) and buybacks ($737M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$698M
Debt$3.9B
Net debt$3.2B

Chemours funds itself: free cash flow was $211M over the last twelve months, and $698M of cash and investments stands against $3.9B of debt.

Where the cash came from and went

Chemours: sources (+) and uses (−) of cash, Q3 2026Chemours: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$149MCash drawn (+) / kept (−)−$78.0MCapital spending−$51.0MAsset & business sales$48.0MOther financing−$47.0MDividends−$13.0MOther investing−$4.0MNet borrowing (+) / repaid (−)−$3.0MExchange rates−$1.0M
Chemours: sources (+) and uses (−) of cash, TTM to Q3 2026Chemours: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing−$1.7BNet borrowing (+) / repaid (−)$1.3BOperating cash flow$400MAsset & business sales$342MCapital spending−$189MCash drawn (+) / kept (−)−$136MDividends−$54.0MOther investing−$8.0MTaxes on employees’ shares−$2.0MExchange rates−$1.0M

From profit to cash

Chemours: net income to operating cash flow, Q3 2026Chemours: net income to operating cash flow, Q3 2026Net income$196MDepreciation & amortization$79.0MStock-based pay$4.0MDeferred taxes−$10.0MGains on disposals−$50.0MInventory−$38.0MPayables$44.0MOther liabilities−$158MIncome taxes payable$34.0MOperating cash flow$149M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 2026461036881
Q2 2026411046481
Q1 2026391207188
Q4 2025481227892
Q3 2025501137588
Q2 2025431066979
Q1 2025441208677
Q4 2024491229477

Every quarter

QuarterOperating cash flowCapital spendingDividendsNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$149M−$51.0M−$13.0M−$3.0M—−$78.0M$98.0M
Q2 2026$158M−$44.0M−$13.0M−$2.0M$1.0M−$108M$114M
Q1 2026−$44.0M−$49.0M−$13.0M$697M$2.0M$109M−$93.0M
Q4 2025$137M−$45.0M−$15.0M$651M—−$59.0M$92.0M
Q3 2025$146M−$41.0M−$13.0M−$5.0M—−$112M$105M
Q2 2025$93.0M−$43.0M−$13.0M−$4.0M—−$39.0M$50.0M
Q1 2025−$112M−$84.0M−$37.0M−$3.0M—$249M−$196M
Q4 2024$138M−$109M−$36.0M−$3.0M$1.0M−$97.0M$29.0M

Chemours: income statement and cash flow

Chemours, Q3 2026: revenue $1.5B (+3% year over year), operating margin 14.4%. The chart follows the revenue to costs, profit and cash.

Chemours: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.